XCRP Stock Overview

Xcorporeal, Inc. is in the process of liquidation and dissolution, pursuant to the plan adopted by board of directors of the company on February 4, 2010. More details

XCRP fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($2K)

Latest financial reports are more than a year old

Shares are highly illiquid

My Notes

Capture your thoughts, links and company narrative

Xcorporeal, Inc. Competitors

Motus GI Holdings

OTCPK:MOTS

US$719.0

ThermoGenesis Holdings

OTCPK:THMO

US$11.1k

BIMI Holdings

OTCPK:BIMI

US$1.4k

Brain Scientific

OTCPK:BRSF

US$932.0k

Price History & Performance

Summary of share price highs, lows and changes for Xcorporeal
Historical stock prices
Current Share Price	US$0.0001
52 Week High	US$0.0001
52 Week Low	US$0.000001
Beta	0
1 Month Change	0%
3 Month Change	n/a
1 Year Change	9,900.00%
3 Year Change	n/a
5 Year Change	-96.00%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	XCRP	US Medical Equipment	US Market
7D	0%	-0.1%	-0.9%
1Y	9,900.0%	13.7%	22.6%

Return vs Industry: XCRP exceeded the US Medical Equipment industry which returned 8.7% over the past year.

Return vs Market: XCRP exceeded the US Market which returned 21.3% over the past year.

Price Volatility

Is XCRP's price volatile compared to industry and market?
XCRP volatility
XCRP Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	8.8%
Market Average Movement	6.4%
10% most volatile stocks in US Market	18.7%
10% least volatile stocks in US Market	3.2%

Stable Share Price: XCRP's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine XCRP's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2001	n/a	n/a	n/a

Xcorporeal, Inc. is in the process of liquidation and dissolution, pursuant to the plan adopted by board of directors of the company on February 4, 2010. The company has formed the liquidating trust, Xcorporeal, Inc. Liquidating Trust, and transferred all of its assets to the trust for the purpose of completing the liquidation and dissolution of the company. Previously, it operated as a medical device company, which was engaged in the development of an extra-corporeal platform technology to be used in devices to replace the function of various human organs.

Xcorporeal, Inc. Fundamentals Summary

How do Xcorporeal's earnings and revenue compare to its market cap?
XCRP fundamental statistics
Market cap	US$1.54k
Earnings (TTM)	-US$2.97m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is XCRP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
XCRP income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$2.97m
Earnings	-US$2.97m

Last Reported Earnings

Sep 30, 2009

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did XCRP perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/13 20:32
End of Day Share Price	2024/10/16 00:00
Earnings	2009/09/30
Annual Earnings	2008/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Xcorporeal, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution